CClinicalTrials.gg
TerminatedNCT03042546Updated Feb 10, 2023Results posted

Calcium Sulfate Spacer in Open Tibia Fractures

A Phase 4 interventional study of Calcium Sulfate and PMMA in Open tíbia Fracture With Sub-segmental Bone Loss, sponsored by University of Washington. Terminated at 1 site in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2023-02-10.

Sponsored by University of Washington · Phase 4, Interventional, and Treatment

Why this study was terminated
Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention. Low enrollment and PI leaving institution
Phase
Phase 4
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

Investigators will compare antibiotic impregnated Calcium sulfate versus PMMA versus nothing in these sub-segmental bone defects.

02

Conditions studied

  • Open tíbia Fracture With Sub-segmental Bone Loss
03

In context

Fractures, Bone

2,261 studies on the registry are indexed under Fractures, Bone; 325 are open to participants now.

This study's enrollment of 1 is below the median of 69 across 1,482 interventional studies indexed under Fractures, Bone.

Browse Fractures, Bone studies →

Lead sponsor

University of Washington is the lead sponsor of 1,397 studies on the registry; 225 are open to participants now.

Of its 154 completed or terminated interventional studies of FDA-regulated products, 132 (86%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Open tibia shaft fracture treated with an IMN

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1 participant (actual)

Study arms

  • Active comparator
    Calcium Sulphate

    Drug: Calcium Sulfate

  • Active comparator
    PMMA

    Drug: PMMA

  • Active comparator
    Nothing

    Other: No treatment

Interventions

  • DrugCalcium Sulfate

    Calcium Sulfate with abx will be used in the defect

  • DrugPMMA

    PMMA with abx will be used in the defect

  • OtherNo treatment

    The defect will not be treated

06

What researchers measure

Primary outcomes

  1. Number of Patients With a Nonunion

    Radiographic healing at one year with no additional surgery

    Time frame: One Year

07

Results

Posted Feb 10, 2023

Participant flow

Participant flow — Overall Study
MilestoneCalcium SulphatePMMANothing
Started000
Completed000
Not completed000

Outcome measures

PrimaryNumber of Patients With a Nonunion

Radiographic healing at one year with no additional surgery

Time frame:
One Year

No measurements were reported for this outcome.

Adverse events

Collected over no one randomized or treated. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Calcium Sulphate———
PMMA———
Nothing———

Baseline characteristics

project abandoned

Age, Categorical
Age, CategoricalCalcium SulphatePMMANothingTotal
<=18 years————
Between 18 and 65 years————
>=65 years————
Age, Continuous
Age, ContinuousCalcium SulphatePMMANothingTotal
Sex: Female, Male
Sex: Female, MaleCalcium SulphatePMMANothingTotal
Female————
Male————
Race and Ethnicity Not Collected
Race and Ethnicity Not CollectedCalcium SulphatePMMANothingTotal
Region of Enrollment
Region of Enrollment(participants)Calcium SulphatePMMANothingTotal
08

Study locations

1 site
  • Harborview Medical Center
    Seattle, Washington 98104, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · May 1, 2016

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — there is no plan to share individual data

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03042546
Lead sponsor
University of Washington
Responsible party
Claude Sagi (Professor, Orthopedics, University of Washington) — Principal investigator
First posted
Feb 3, 2017
Start date
Feb 1, 2017
Primary completion
May 29, 2018
Completion
May 29, 2018
Results posted
Feb 10, 2023
Last update
Feb 10, 2023

Study contacts

Claude Sagi
principal investigator · University of Washington

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion